TRANSCRIPTIONAL REGULATION OF INTERLEKIN 2 IN SLE T CELLS

REFERENCES

• A.M., Draeger, A.J., Swaak. H.G. van den Brink, and L.A. Aarden, T cell function in systemic lupus erythematosus: Normal production of and responsiveness to interleukin 2. Clin. Exp. Immunol.. 64: 80–87, 1986
   PubMed Web of Science ®Google Scholar
• D.A., Horwitz, H., Wang, J.D., Gray. Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: Increased interleukin-2 but not interleukin-4 mRNA. Lupus. 3: 423–428, 1994, [CSA]
   PubMed Web of Science ®Google Scholar
• J., Alcocer-Varela, D., Alarcon-Segovia. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest.. 69: 1388–1392, 1982
   PubMed Web of Science ®Google Scholar
• P., de Faucal, A., Godard, M.A., Peyrat, J.F., Moreau, J.P., Soulillou. Impaired IL2 production by lymphocytes of patients with systemic lupus erythematosus. Ann. Immunol., (Paris). 135D: 161–172, 1984
   PubMedGoogle Scholar
• M., Funauchi, S., Ikoma, H., Enomoto, A., Horiuchi. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand. J. Rheumatol.. 27: 219–224, 1998, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T., Hayama, N., Kubo, E., Ikeda, H., Hashimoto, S., Sawada, T., Horie. Functional T cell subpopulations responsible for hyposecretion of IL-2 in patients with systemic lupus erythematosus. Clin. Rheumatol.. 10(4)388–394, Dec. 1991
   PubMedGoogle Scholar
• M., Linker-Israeli, A.C., Bakke, R.C., Kitridou, S., Gendler, S., Gillis, D.A., Horwitz. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol.. 130(1)2651–2655, June. 1983
   PubMedGoogle Scholar
• R.M., McKenna, J.A., Wilkins, R.J., Warrington. Lymphokine production in rheumatoid arthritis and systemic lupus erythematosus. J. Rheumatol.. 15: 1639–1642, 1988
   PubMed Web of Science ®Google Scholar
• Y., Murakawa, T., Sakane. Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum.. 31: 826–833, 1988
   PubMedGoogle Scholar
• Y., Murakawa, S., Takada, Y., Ueda, N., Suzaki, T., Hoshino, T., Sakane. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J. Immunol.. 134(1)187–195, Jan. 1985
   PubMedGoogle Scholar
• E.E., Solomou, Y.T., Juang, M.F., Gourley, G.M., Kammer, G.C., Tsokos. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol.. 166: 4216–4222, 2001
   PubMed Web of Science ®Google Scholar
• M.N., Sato, P., Minoprio, S., Avrameas, T., Ternynck. Defects in the regulation of anti-DNA antibody production in aged lupus-prone (NZB x NZW)F1 mice: Analysis of T-cell lymphokine synthesis. Immunology. 85: 26–32, 1995
   PubMedGoogle Scholar
• W., Barcellini, G.P., Rizzardi, M.O., Borghi, F., Nicoletti, C., Fain, N., Del Papa, P.L., Meroni. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: Lack of relationship with clinical disease activity. Lupus. 5(2)139–145, Apr. 1996, [CSA]
   PubMedGoogle Scholar
• G.C., Tsokos, H.K., Wong, E.J., Enyedy, M.P., Nambiar. Immune cell signaling in lupus. Curr. Opin. Rheumatol.. 12: 355–363, 2000, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• G.C., Tsokos, B., Kovacs, P.P., Sfikakis, S., Theocharis, S., Vogelgesang, C.S., Via. Defective antigen-presenting cell function in patients with systemic lupus erythematosus. Arthritis Rheum.. 39(4)600–609, Apr. 1996
   PubMedGoogle Scholar
• C., Alvarado, J., Alcocer-Varela, L., Llorente, Y., Richaud-Patin, M., Cerbon, D., Alarcon-Segovia. Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus. J. Autoimmun.. 7(6)763–773, Dec. 1994, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• C.S., Via, G.C., Tsokos, B., Bermas, M., Clerici, G.M., Shearer. T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects. J. Immunol.. 151: 3914–3922, 1993
   PubMed Web of Science ®Google Scholar
• N., Isakov, A., Altman. Protein kinase C(theta) in T cell activation. Annu. Rev. Immunol.. 20: 761–794, 2002, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.E., Solomou, Y.T., Juang, G.C., Tsokos. Protein kinase C-theta participates in the activation of cyclic AMP-responsive element-binding protein and its subsequent binding to the −180 site of the IL-2 promoter in normal human T lymphocytes. J. Immunol.. 166: 5665–5674, 2001
   PubMedGoogle Scholar
• J.D., Powell, C.G., Lerner, G.R., Ewoldt, R.H., Schwartz. The −180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J. Immunol.. 163: 6631–6639, 1999
   PubMedGoogle Scholar
• J.D., Powell, J.A., Ragheb, S., Kitagawa-Sakakida, R.H., Schwartz. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol. Rev.. 165: 287–300, 1998, [CSA]
   PubMedGoogle Scholar
• G.M., Kammer. Deficient protein kinase a in systemic lupus erythematosus: a disorder of T lymphocyte signal transduction. Ann. NY Acad. Sci.. 968: 96–105, 2002, [CSA]
   PubMedGoogle Scholar
• I.U., Khan, D., Laxminarayana, G.M., Kammer. Protein kinase A RI beta subunit deficiency in lupus T lymphocytes: Bypassing a block in RI beta translation reconstitutes protein kinase A activity and augments IL-2 production. J. Immunol.. 166: 7600–7605, 2001
   PubMed Web of Science ®Google Scholar
• G.M., Kammer, G.C., Tsokos. Abnormal T lymphocyte signal transduction in systemic lupus erythematosus. Curr. Dir. Autoimmun.. 5: 131–150, 2002, [CSA]
   PubMedGoogle Scholar
• A.K., Dayal, G.M., Kammer. The T cell enigma in lupus. Arthritis Rheum.. 39: 23–33, 1996
   PubMed Web of Science ®Google Scholar
• T.J., Novak, P.M., White, E.V., Rothenberg. Regulatory anatomy of the murine interleukin-2 gene. Nucleic Acids Res.. 18: 4523–4533, 1990
   PubMed Web of Science ®Google Scholar
• W.F., Davidson, J.B., Roths, K.L., Holmes, E., Rudikoff, H.C., Morse. III, Dissociation of severe lupus-like disease from polyclonal B cell activation and IL 2 deficiency in C3H-lpr/lpr mice. J. Immunol.. 133: 1048–1056, 1984
   PubMed Web of Science ®Google Scholar
• W., Ofosu-Appiah, V., Aiello, G., Sfeir, D., Viti. Isolation and functional characterization of IL-2 responsive T cell clones from NZB x NZW F1 mice. J. Autoimmun.. 9: 617–627, 1996, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• H.E., Liang, et al, Atypical signaling defects prevent IL-2 gene expression in lpr/lpr CD4-CD8- cells. J. Biomed. Sci.. 5: 297–304, 1998, [CROSSREF]
   PubMedGoogle Scholar
• S., Nagata. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: A lesson from the mouse model. J. Hum. Genet.. 43: 2–8, 1998, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C., Mohan, L., Morel, P., Yang, E.K., Wakeland. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthritis Rheum.. 41: 1652–1662, 1998, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O., Stutman, E.J., Yunis, R.A., Good. Deficient immunologic functions of NZB mice. Proc. Soc. Exp. Biol. Med.. 127: 1204–1207, 1968
   PubMedGoogle Scholar
• H., Ishida, et al, Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med.. 179: 305–310, 1994, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K., Barton, et al, Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature. 379: 81–85, 1996, [CROSSREF]
   PubMedGoogle Scholar
• C.C., Hughes, J.S., Pober. Transcriptional regulation of the interleukin-2 gene in normal human peripheral blood T cells. Convergence of costimulatory signals and differences from transformed T cells. J. Biol. Chem.. 271: 5369–5377, 1996, [CROSSREF]
   PubMedGoogle Scholar
• J., Jain, C., Loh, A., Rao. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol.. 7: 333–342, 1995, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.V., Rothenberg, S.B., Ward. A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. Proc. Natl. Acad. Sci. USA. 93: 9358–9365, 1996, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.K., Abbas. Die and let live: eliminating dangerous lymphocytes. Cell. 84(5)655–657, Mar. 1996, [CROSSREF]
   PubMedGoogle Scholar
• J.P., Viola, A., Rao. Molecular regulation of cytokine gene expression during the immune response. J. Clin. Immunol.. 19: 98–108, 1999, [CROSSREF]
   Google Scholar
• A., Rao, C., Luo, P.G., Hogan. Transcription factors of the NFAT family: Regulation and function. Annu. Rev. Immunol.. 15: 707–747, 1997, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F., Macian, C., Lopez-Rodriguez, A., Rao. Partners in transcription: NFAT and AP-1. Oncogene. 20: 2476–2489, 2001, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G., Wiederrecht, E., Lam, S., Hung, M., Martin, N., Sigal. The mechanism of action of FK-506 and cyclosporin A. Ann. NY Acad. Sci.. 696: 9–19, 1993, [CSA]
   PubMed Web of Science ®Google Scholar
• M.L., Schmitz, S., Bacher, M., Kracht. I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem. Sci.. 26: 186–190, 2001, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T., Hayashi, D., Faustman. NOD mice are defective in proteasome production and activation of NF-kappaB. Mol. Cell Biol.. 19: 8646–8659, 1999
   PubMed Web of Science ®Google Scholar
• M.R., Boothby, A.L., Mora, D.C., Scherer, J.A., Brockman, D.W., Ballard. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-kappaB. J. Exp. Med.. 185: 1897–1907, 1997, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B., Mayr, M., Montminy. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol.. 2: 599–609, 2001, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H., Asahara, B., Santoso, E., Guzman, K., Du, P. A., Kole, I., Davidson, M., Montminy. Chromatin-dependent cooperativity between constitutive and inducible activation domains in CREB. Mol. Cell Biol.. 21(23)7892–7900, Dec. 2001, [CROSSREF]
   PubMedGoogle Scholar
• M., Montminy. Transcriptional regulation by cyclic AMP. Annu. Rev. Biochem.. 66: 807–822, 1997, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D., De. Cesare, and P. Sassone-Corsi, Transcriptional regulation by cyclic AMP-responsive factors. Prog. Nucleic Acid Res. Mol. Biol.. 64: 343–369, 2000, [CSA]
   PubMedGoogle Scholar
• P., Sassone-Corsi. Transcription factors responsive to cAMP. Annu. Rev. Cell Dev. Biol.. 11: 355–377, 1995, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• N.S., Foulkes, E., Borrelli, P., Sassone-Corsi. CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell. 64: 739–749, 1991
   PubMed Web of Science ®Google Scholar
• P.B., Daniel, L., Rohrbach, J.F., Habener. Novel cyclic adenosine 3′,5′-monophosphate (cAMP) response element modulator theta isoforms expressed by two newly identified cAMP-responsive promoters active in the testis. Endocrinology. 141: 3923–3930, 2000, [CSA]
   PubMed Web of Science ®Google Scholar
• L., Monaco, P., Sassone-Corsi. Cross-talk in signal transduction: Ras-dependent induction of cAMP-responsive transcriptional repressor ICER by nerve growth factor. Oncogene. 15: 2493–2500, 1997, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• C.C., Broder, R.G., Collman. Chemokine receptors and HIV. J. Leukoc. Biol.. 62(1)20–29, July. 1997, [CSA]
   PubMedGoogle Scholar
• J., Bodr, J., Bodorova, R.E., Gress. Suppression of T cell function: a potential role for transcriptional repressor ICER. J. Leukoc. Biol.. 67: 774–779, 2000, [CSA]
   PubMedGoogle Scholar
• U., de Grazia, M.P., Felli, A., Vacca, A.R., Farina, M., Maroder, L., Cappabianca, M., Farina, I., Scepanti, L., Frati. Positive and negative regulation of the composite octamer motif of the interleukin 2 enhancer by AP-1, Oct-2, and retinoic acid receptor. J. Exp. Med.. 180: 1485–1497, 1994, [CROSSREF]
   PubMedGoogle Scholar
• L.M., Corcoran, M., Karvelas. Oct-2 is required early in T cell-independent B cell activation for G1 progression and for proliferation. Immunity. 1: 635–645, 1994, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• J., Rengarajan, S.J., Szabo, L.H., Glimcher. Transcriptional regulation of Th1/Th2 polarization. Immunol. Today. 21: 479–483, 2000, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• C.B., Thompson, C.Y., Yang, J.C., Ho, P.R., Bohjanen, B., Petryniak, C.H., June, S., Miesfeldt, L., Zhang, G.J., Nabel, B., Karpinski. cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. Mol. Cell Biol.. 12(3)1043–1053, Mar. 1992
   PubMedGoogle Scholar
• H.K., Wong, G.M., Kammer, G., Dennis, G.C., Tsokos. Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J. Immunol.. 163: 1682–1689, 1999
   PubMed Web of Science ®Google Scholar
• T., Horiuchi, D., Himeji, H., Tsukamoto, S., Harashima, C., Hashimura, K., Hayashi. Dominant expression of a novel splice variant of caspase-8 in human peripheral blood lymphocytes. Biochem. Biophys. Res. Commun.. 272(3)877–881, June 16. 2000, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• T.M., Herndon, Y.T., Juang, E.E., Solomou, S.W., Rothwell, M.F., Gourley, G.C., Tsokos. Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity. Clin. Immunol.. 103(2)145–153, May. 2002, [CROSSREF]
   PubMedGoogle Scholar
• P., Burgos, C., Metz, P., Bull, R., Pincheira, L., Massardo, C., Errazuriz, M.R., Bono, S., Jacobelli, A., Gonzalez. Increased expression of c-rel, from the NF-kappaB/Rel family, in T cells from patients with systemic lupus erythematosus. J. Rheumatol. 27(1)116–127, Jan. 2000
   PubMedGoogle Scholar
• N.S., Foulkes, B.M., Laoide, F., Schlotter, P., Sassone-Corsi. Transcriptional antagonist cAMP-responsive element modulator (CREM) down-regulates c-fos cAMP-induced expression. Proc. Natl. Acad. Sci. USA. 88: 5448–5452, 1991, [CSA]
   PubMedGoogle Scholar
• K., Tenbrock, Y.T., Juang, M.F., Gourley, M.P., Nambiar, G.C., Tsokos. Anti-sense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cell from patients with systemic lupus erythematosus. J. Immunol.. 169(8)4147–4152, Oct. 15. 2002
   PubMed Web of Science ®Google Scholar
• J.M., Horowitz. Regulation of transcription by the retinoblastoma protein. Genes Chromosomes Cancer. 6: 124–131, 1993
   PubMedGoogle Scholar
• G.M., Kammer, T.M., Haqqi, P., Hasler, C.J., Malemud. The effect of circulating serum factors from patients with systemic lupus erythematosus on protein kinase A (PKA) activity and PKA-dependent protein phosphorylation in T lymphocytes. Clin. Immunol. Immunopathol.. 67: 8–16, 1993, [CROSSREF]
   PubMedGoogle Scholar
• D., Masquilier, P., Sassone-Corsi. Transcriptional cross-talk: Nuclear factors CREM and CREB bind to AP-1 sites and inhibit activation by Jun. J. Biol. Chem.. 267: 22460–22466, 1992
   PubMed Web of Science ®Google Scholar
• Y.T., Juang, E.E., Solomou, B., Rellahan, G.C., Tsokos. Phosphorylation and O-linked glycosylation of Elf-1 leads to its translocation to the nucleus and binding to the promoter of the TCR zeta-chain. J. Immunol.. 168: 2865–2871, 2002
   PubMed Web of Science ®Google Scholar
• J.I., Sin, D.B., Weiner. Improving DNA vaccines targeting viral infection. Intervirology. 43: 233–246, 2000, [CSA], [CROSSREF]
   PubMedGoogle Scholar